Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study

Author:

Sunami Kazutaka1,Fuchida Shin‐ichi2,Suzuki Kenshi3,Ri Masaki4ORCID,Matsumoto Morio5,Shimazaki Chihiro2,Asaoku Hideki6,Shibayama Hirohiko7,Ishizawa Kenichi8,Takamatsu Hiroyuki9,Ikeda Takashi10ORCID,Maruyama Dai11ORCID,Imada Kazunori12,Uchiyama Michihiro13,Kiguchi Toru1415,Iyama Satoshi16,Murakami Hirokazu17,Onishi Reiko18,Tada Keisuke18,Iida Shinsuke4ORCID

Affiliation:

1. Department of Hematology National Hospital Organization, Okayama Medical Center Okayama Japan

2. Department of Hematology Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center Kyoto Japan

3. Myeloma/Amyloidosis Center Japanese Red Cross Medical Center Tokyo Japan

4. Department of Hematology and Oncology Nagoya City University Institute of Medical and Pharmaceutical Sciences Nagoya Japan

5. Department of Hematology National Hospital Organization Shibukawa Medical Center Shibukawa Japan

6. Hiroshima Red Cross Blood Center Hiroshima Japan

7. Department of Hematology National Hospital Organization Osaka National Hospital Osaka Japan

8. Department of Third Internal Medicine Division of Hematology and Cell Therapy Yamagata University Faculty of Medicine Yamagata Japan

9. Department of Hematology Faculty of Medicine Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan

10. Division of Hematology and Stem Cell Transplantation Shizuoka Cancer Center Shizuoka Japan

11. Department of Hematology National Cancer Center Hospital Tokyo Japan

12. Department of Hematology Japanese Red Cross Osaka Hospital Osaka Japan

13. Department of Hematology Japanese Red Cross Society Suwa Hospital Suwa Japan

14. Department of Hematology Chugoku Central Hospital Fukuyama Japan

15. Division of Diabetes, Endocrinology and Hematology Dokkyo Medical University Saitama Medical Center Saitama Japan

16. Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan

17. Department of Laboratory Sciences Gunma University Graduate School of Health Sciences Maebashi Japan

18. Sanofi, Research and Development Tokyo Japan

Funder

Sanofi

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3